Senmiao Ni

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Topics

Metastatic Colorectal Cancer

Top Venues

Statistical methods in medical research

Biometrical journal. Biometrische Zeitschrift

Journal of applied statistics

Journal of biopharmaceutical statistics

This page only lists publications with an associated author ORCID identifier.

Publications

Senmiao Ni, Zihang Zhong, Zhiwei Jiang, Yang Zhao, Jingwei Wu, Hao Yu, Jianling Bai
Beta spending function based on conditional power in group sequential design. Biometrical journal. Biometrische Zeitschrift 66 (3) (2024)
Senmiao Ni, Zihang Zhong, Yang Zhao, Feng Chen, Jingwei Wu, Hao Yu, Jianling Bai
Sample size estimation for stratified cluster randomization trial with survival endpoint. Statistical methods in medical research 33 (5) (2024)
Senmiao Ni, Zihang Zhong, Yang Zhao, Feng Chen, Jingwei Wu, Hao Yu, Jianling Bai
Sample size estimation for stratified cluster randomization trial with survival endpoint. Statistical methods in medical research (2024)
Senmiao Ni, Zihang Zhong, Zhiwei Jiang, Yang Zhao, Jingwei Wu, Hao Yu, Jianling Bai
Beta spending function based on conditional power in group sequential design. Biometrical journal. Biometrische Zeitschrift 66 (3) (2024)
Senmiao Ni, Zihang Zhong, Yang Zhao, Feng Chen, Jingwei Wu, Hao Yu, Jianling Bai
Sample size estimation for stratified cluster randomization trial with survival endpoint. Statistical methods in medical research 33 (5) (2024)
Zihang Zhong, Min Yang, Senmiao Ni, Lixin Cai, Jingwei Wu, Jianling Bai, Hao Yu
The heterogeneity effect of surveillance intervals on progression free survival. Journal of applied statistics 51 (4) (2022)
Zihang Zhong, Min Yang, Senmiao Ni, Lixin Cai, Jingwei Wu, Jianling Bai, Hao Yu
The heterogeneity effect of surveillance intervals on progression free survival. Journal of applied statistics 51 (4) (2022)
Senmiao Ni, Quanji Yu, Zihang Zhong, Min Yang, Yang Zhao, Jingwei Wu, Jianling Bai, Hao Yu
Risk difference, relative risk, and odds ratio for non-inferiority clinical trials with risk rate endpoint. Journal of biopharmaceutical statistics (2022)